Element Biosciences Lands $175M Series E From Samsung as Genomics Infrastructure Heats Up

Element Biosciences has raised an upsized Series E financing that includes a $175M investment from Samsung Electronics, along with additional undisclosed participation from other investors. The San Diego-based company develops DNA sequencing and multiomics platforms, including AVITI, AVITI24, and VITARI. Element Biosciences says the new capital will accelerate commercialization, expand its global footprint, and advance products across research, translational science, and diagnostic applications.

The financing is notable because Samsung Electronics is not simply investing in another life sciences company. It is increasing exposure to the infrastructure layer behind genomic research, multiomics, and future data-driven healthcare. For founders, investors, and operators, the announcement highlights a broader market reality: capital continues flowing toward platforms that generate, organize, and interpret biological data at scale.

What Happened

Element Biosciences announced an upsized Series E financing that includes a $175M investment from Samsung Electronics. Additional investors participated in the round, although their identities and investment amounts were not publicly disclosed. Founded in 2017 by Molly He, PhD, Michael Previte, PhD, and Matthew Kellinger, PhD, Element Biosciences has spent the past several years building sequencing and multiomics platforms designed to give researchers greater flexibility and broader access to advanced genomic technologies.

The company's leadership team includes CEO Molly He, CTO and SVP of Advanced Research Michael Previte, VP of Biochemistry Matthew Kellinger, CFO Logan Zinser, Chief People Officer Brian Stolz, and SVP of Corporate and Business Development Yaron Hakak, PhD. Samsung Electronics also participated in Element Biosciences' $277M Series D financing in 2024, making the Series E investment part of a longer strategic relationship rather than a first-time bet.

The financing follows a $276M Series C completed in 2021 and a $277M Series D announced in 2024. Both rounds helped Element Biosciences scale commercialization efforts, expand its product portfolio, and strengthen its position within the genomics infrastructure market. Element Biosciences operates from the Alexandria Tech Center in San Diego, one of the most active life sciences hubs in the United States.

Why This Matters

The sequencing market has historically rewarded scale. Larger systems, larger laboratories, larger budgets. That dynamic created extraordinary innovation, but it also created concentration. Element Biosciences entered the market with a different thesis, focusing on making sequencing and multiomics tools more accessible while maintaining scientific performance.

That strategy produced a growing portfolio that now includes the AVITI sequencing platform, the AVITI24 5D Multiomics System, and the recently introduced VITARI high-throughput benchtop platform. AVITI established Element Biosciences as a sequencing challenger. AVITI24 expanded the company's capabilities into integrated multiomics workflows. VITARI extends the platform portfolio into higher-throughput sequencing while maintaining a benchtop footprint designed to broaden accessibility.

What Samsung Electronics appears to be buying into is not a single instrument. It is a platform strategy. Genomics is increasingly becoming a data business, and the organizations creating long-term value are not merely generating biological information. They are building ecosystems capable of turning that information into actionable insights.

That distinction matters because the future of healthcare, diagnostics, drug discovery, and precision medicine depends on the quality, scale, and accessibility of biological data.

Market Context

The genomics industry is entering a new phase. For years, conversations centered on sequencing costs. The race was often framed around who could deliver cheaper genomes and faster throughput. Those conversations still matter, but the market has become more complex.

Researchers now want integrated workflows. They want sequencing, transcriptomics, spatial biology, protein analysis, and downstream interpretation to work together rather than exist as disconnected islands. That shift helps explain why multiomics has become one of the most closely watched categories in life sciences, and Element Biosciences sits directly inside that trend.

The company's roadmap now spans sequencing, multiomics, tissue profiling, and future diagnostic applications. The strategy is less about selling a machine and more about becoming part of the infrastructure stack supporting modern biological research.

When viewed through that lens, Samsung Electronics' investment looks less like a standalone financing event and more like a strategic bet on the future architecture of biological data.

Competitive Landscape

Element Biosciences operates in one of the most competitive markets in life sciences. Established sequencing companies such as Illumina continue to invest heavily in throughput, workflow efficiency, software ecosystems, and large-scale sequencing infrastructure. At the same time, emerging companies across spatial biology, multiomics, and precision medicine are attempting to build the next generation of research platforms.

Element Biosciences has attempted to differentiate itself through platform flexibility and expanding product breadth. AVITI established the company's presence in sequencing. AVITI24 expanded into multiomics. VITARI extends the portfolio further by addressing higher-throughput sequencing needs while remaining within a benchtop form factor.

The broader competitive question is no longer simply who can sequence DNA. The question increasingly becomes who can create the most useful biological information ecosystem.

That is a different contest entirely.

What This Signals

The financing sends several signals to the market. First, investor interest in life sciences infrastructure remains strong despite broader venture market volatility. Second, strategic investors continue to view biology as a data-intensive industry that will increasingly intersect with AI, analytics, and advanced computing. Third, platform companies are attracting attention over point-solution businesses.

Investors are looking for organizations capable of supporting multiple workflows, serving multiple customer segments, and expanding across adjacent markets over time. Element Biosciences appears to be positioning itself precisely in that category.

The company reports technology usage in 400+ publications, nearly 30 unique patents, and customers across 40+ countries. Those metrics suggest growing adoption beyond early-stage experimentation.

The Bigger Industry Shift

Every technology cycle creates a new infrastructure layer. Cloud computing needed data centers. Artificial intelligence needed GPUs. Modern biology increasingly needs scalable systems capable of generating, organizing, and interpreting biological information. That is where companies like Element Biosciences become strategically important.

The market often focuses on applications because applications are visible. Infrastructure tends to be quieter, less glamorous, and less likely to dominate headlines. Yet infrastructure is where many of the largest long-term outcomes are created.

Samsung Electronics' $175M investment suggests sophisticated capital sees continued opportunity in the foundational layers of genomics and multiomics. Not because the story is finished, but because the amount of biological data being created continues to expand. Researchers are asking larger questions, healthcare systems are becoming more data dependent, drug development is becoming more computational, and the tools required to support those realities are becoming increasingly valuable.

For a broader understanding of how genomics is shaping the future of medicine, the National Human Genome Research Institute provides extensive research and industry context around genomic science and precision medicine.